Is Vigabatrin available in China? How much does it cost?
Vigabatrin is an anti-epileptic drug mainly used to treat refractory epilepsy, especially infantile spasms (West syndrome). The condition usually appears within a few months of birth and is characterized by brief muscle twitching and loss of consciousness. If left untreated, infantile spasms can lead to severe cognitive and developmental disabilities. Therefore, timely and effective drug treatment is crucial.
The mechanism of action of Vigabatrin is by inhibiting γ-aminobutyric acid (GABA) aminotransferase, thereby increasing the concentration of GABA in the brain. GABA is an important inhibitory neurotransmitter that can inhibit the over-excitation of neurons and reduce the occurrence of epileptic seizures. This mechanism allows Vigabatrin to show better efficacy in many cases where conventional anti-epileptic drugs are ineffective, especially in the treatment of infants and other refractory epilepsy types.

At present, Vigabatrin has been launched in the Chinese market and has been included in medical insurance. According to market information, the price of Vigabatrin is 500mg*30bags, and the selling price is around more than one thousand yuan. Due to the coverage of medical insurance, eligible patients can enjoy certain reimbursements and reduce their financial burden. Specific medical insurance policies and reimbursement ratios may vary by region. Patients are advised to consult the local hospital pharmacy or medical insurance center for detailed information.
In other markets, the original drug in Hong Kong, China, is also available in 500mg*100 bags, and the price is more than a thousand yuan, while some foreign generic drugs provide more economical options. The price of 500mg of the same specifications is around a few hundred yuan, and the ingredients of the drugs are basically the same.
Overall, Vigabatrin, as an effective antiepileptic drug, provides an important treatment option for patients with refractory epilepsy. Its listing and medical insurance coverage provide patients with better financial support, allowing more patients to receive necessary treatment. When using, patients should follow their doctor's instructions to ensure safety and effectiveness.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)